Susquehanna Fundamental Investments’s Cyclerion Therapeutics CYCN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$104K	Sell	4,706 -57	-1%	-$1.37K	﹤0.01%	1446
2021 Q4	$164K	Sell	4,763 -356	-7%	-$16.8K	﹤0.01%	1283
2021 Q3	$314K	Sell	5,119 -160	-3%	-$10.5K	0.01%	1391
2021 Q2	$412K	Buy	+5,279	New	+$331K	0.01%	1237
2021 Q1	–	Sell	-750	Closed	-$46K	–	1547
2020 Q4	$46K	Sell	750 -145	-16%	-$9.88K	﹤0.01%	1454
2020 Q3	$109K	Buy	+895	New	+$102K	﹤0.01%	1275

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Susquehanna Fundamental Investments's CYCN Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Cyclerion Therapeutics (CYCN) stake by 1.2% in Q1 2022, selling an estimated $1.37K and leaving 4,706 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Susquehanna Fundamental Investments first reported a position in CYCN in Q3 2020 and has held it in 6 quarters since. The position peaked at $412K in Q2 2021. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

Susquehanna Fundamental Investments held 4,706 shares of Cyclerion Therapeutics worth $104K as of Q1 2022.
Susquehanna Fundamental Investments sold 57 Cyclerion Therapeutics shares in Q1 2022, an estimated $1.37K.
Cyclerion Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1446 holding.
Susquehanna Fundamental Investments first reported a position in Cyclerion Therapeutics in Q3 2020 and has held it in 6 quarters since.
Susquehanna Fundamental Investments's Cyclerion Therapeutics position peaked at $412K in Q2 2021.
50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.